How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes

Diabetes Therapy

Volumn 8, Issue 1, 2017, Pages 9-22

  Muñoz Garach, Araceli ^a,b   Molina Vega, María ^a,b   Tinahones, Francisco J ^a,b,c  

^a Virgen de la Victoria Clinic Hospital   (Spain)

^b IBIMA foundation ^*  (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Basal insulin peglispro; Efficacy; Hypoglycemia; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; INSULIN GLARGINE; INSULIN PEGLISPRO; ISOPHANE INSULIN; TRIACYLGLYCEROL;

BACKACHE; CHEMISTRY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPOGLYCEMIA; LIVER INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 85012188199     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-016-0214-7     Document Type: Review

References (35)

1. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 2012;166:159–70.
2. Chan JC, Gagliardino JJ, Baik SH, et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care. 2009;32:227–33.
3. Esposito K, Giugliano D. Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. Expert Opin Biol Ther. 2012;12:209–21.
4. Owens David R, Matfin Glenn, Monnier Louis. “Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev. 2014;30(2):104–19.
5. Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014;16(6):483–91.
6. Beals JM, Cutler GB, Doyle B, et al. Pegylated insulin lispro compounds. U.S. patent 20090312236 A1.
7. Hansen RJ, Cutler GB, Vick A, et al. LY260541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetes. 2012;61(Suppl. 1):A228.
8. Madsbad S. LY2605541–a preferential hepato-specific insulin analogue. Diabetes. 2014;63(2):390–2.
9. Hinds KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev. 2002;54:505–30.
10. Caparrotta1 TM, Evans M. PEGylated insulin Lispro, (LY2605541)—a new basal insulin analogue. Diabetes Obesity Metab 2014. 16: 388–95.
11. Knadler MP, Nguyen T-H, Campanale KM, De Veer MJ, Beals JM, Porter CJH. Lymphatic absorption of basal insulin peglispro (BIL) in sheep. Diabetes. 2015;64:A262.
12. Kiselyov VV, Ding L, Wu GY, Moyers J. Analysis of basal insulin peglispro (BIL) binding kinetics with the use of a harmonic oscillator insulin receptor binding model. Diabetes. 2015;64:A264–5.
13. Beals JM, Cutler GB, Vick A, et al. LY2605541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetologia. 2012;55(Suppl. 1):S23.
14. Linnebjerg H, Choi SL, Lam ECQ, Mace KF, Hodgson TS, Sinha VP. Pharmacokinetics (PK) of the novel, long-acting basal insulin LY2605541 in subjects with varying degrees of renal function. Diabetologia. 2012;55(Suppl. 1):S379.
15. Moore MC, Smith MS, Mace KF, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes. 2014;63(2):494–504.
16. Sinha VP, Howey DC, Kwang Wei Soon D, et al. Single-dose pharmacokinetics and glucodynamics of the novel long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol. 2014;54:792–9.
17. Garhyan P, Choi SL, Smith LaBell E, Knadler MP, Prince MJ. Clinical pharmacokinetics (PK) and renal elimination of basal insulin peglispro (BIL) and its polyethylene glycol (PEG)-containing products. Diabetes. 2015;64:LB22.
18. Sinha VP, Heise T, Howey DC, Choi SL, Mace KF. Steady-state pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 dosed once-daily (QD) in patients with type 2 diabetes mellitus (T2DM). Diabetes Obes Metab. 2014;16:344–50.
19. Kiss I, Arnold G, Bøttcher S, Thrane M, Haahr H. Insulin degludec has similar pharmacokinetic properties in subjects with renal impairment and subjects with normal renal function. Diabetes. 2012;61(Suppl. 1):A296–7.
20. Topp BG, Geiser JS, Soon DKW, et al. Effects of a novel PEGylated basal insulin, LY2605541, on hepatic glucose output and muscle glucose uptake: simulations based on data from euglycaemic clamp studies. Diabetologia. 2012;55(Suppl. 1):S376.
21. Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care. 2014;37(9):2609–15.
22. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, vs. insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35:2140–7.
23. Bastyr EJ, Bergenstal RM, Rosenstock J, Prince MJ, Qu Y, Jacober SJ. Lower glucose variability and hypoglycaemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. Diabetologia. 2012;55(Suppl. 1):S378.
24. Davies MJ, Russell-Jones D, Selam J-L, Bailey TS, Kerényi Z, Luo J, Bue-Valleskey J, Iványi T, Hartman ML, Jacobson JG, Jacober SJ. Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab. 2016;18(11):1055–64.
25. Blevins T, Pieber TR, Colón Vega G, Zhang S, Bastyr EJ III. Chang.AM. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Diabetes Obes Metab. 2016;18(11):1072–80.
26. Buse JB, Rodbard HW, Trescoli Serrano C, et al. A randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes mellitus previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39(92):100.
27. Grunberger G, Chen L, Rodriguez A, Tinahones FJ, Jacober SJ, Bue-Valleskey J, On behalf of the IMAGINE 6 Investigators. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial. Diabetes Obes Metab. 2016;18(11):1034–42.
28. Rosenstock J, Marre M, Qu Y, Zhang S, Bastyr EJ III, Prince MJ. Chang AM Reduced Nocturnal Hypoglycemia with Basal Insulin Peglispro Compared to Insulin Glargine: Pooled Analyses of 5 Randomized Controlled Trials. Diabetes Obes Metab. 2016;18(11):1093–7.
29. Jacober SJ, Rosenstock J, Bergenstal RM, Prince MJ, Qu Y, Beals JM. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in type 1 diabetes and type 2 diabetes. Diabetologia. 2012;55(Suppl. 1):S377.
30. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes a randomized, crossover study. Diabetes Care. 2012;36:522–8.
31. Dornhorst A, Luddeke H-J, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract. 2008;62:659–65.
32. Cusi K, Sanyal AJ, Zhang S, Hoogwerf BJ, Chang AM, Jacober SJ, Bue-Valleskey JM, Higdon AN, Bastyr EJ III, Haupt A, Hartman ML. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes Obes Metab. 2016;18(11):1050–8.
33. Ginsberg H, Cariou B, Orchand T, Chen L, Luo J, Bastyr EJ III, Bue-Valleskey J, Chang AM, Ivanyi T, Jacober SJ, Jacobson JG, Hoogwerf BJ. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials. Diabetes Obes Metab. 2016;18(11):1089–92.
34. Ginsberg H, Cariou B, Orchard TJ, et al. Lipid changes during 26-wk treatment with the novel basal insulin peglispro (BIL) vs. insulin glargine (GL) or insulin NPH in 6 IMAGINE trials. Diabetes. 2015;64:A251.
35. Hoogwerf BJ, Lincoff AM, Rodriguez A, Chen L, Qu Y. Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovasc Diabetol. 2016;15:78.